LMAT insider trading
NasdaqGM HealthcareLEMAITRE VASCULAR INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About LEMAITRE VASCULAR INC
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Company website: www.lemaitre.com
LMAT insider activity at a glance
FilingIQ has scored 1,565 insider transactions for LMAT since Jan 21, 2015. The most recent filing in our index is dated May 8, 2026.
Across the full history, 3 open-market purchases
and 391 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LMAT insider trades is 67.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest LMAT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading LMAT
Frequently asked
- How many insider trades does FilingIQ track for LMAT?
- FilingIQ tracks 1,565 Form 4 insider transactions for LMAT (LEMAITRE VASCULAR INC), covering filings from Jan 21, 2015 onwards. 118 of those were filed in the last 90 days.
- Are LMAT insiders net buyers or net sellers?
- Across the full Form 4 history for LMAT, 3 transactions (0%) were open-market purchases and 391 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LMAT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LMAT in?
- LEMAITRE VASCULAR INC (LMAT) is classified in the Healthcare sector, specifically Medical Instruments & Supplies, with a current market capitalisation of $2.07B.
Methodology & sources
Every LMAT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.